Diagnostic Test For Pancreas Function — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diagnostic test for pancreas function. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
3
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Diagnostic Test For Pancreas Function

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bracco 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diagnostic test for pancreas function. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sincalide
SINCALIDE
 Bracco 3 70 — 2038-04-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11110063 Sincalide method of use 70 2038-04-20
11318100 Sincalide method of use 70 2038-04-20
11737983 Sincalide method of use 70 2038-04-20

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11110063 Sincalide method of use 70 2038-04-20
11318100 Sincalide method of use 70 2038-04-20
11737983 Sincalide method of use 70 2038-04-20

Related